Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2021.
Third Quarter and Recent Highlights:
"This past quarter we have been actively focused on meeting our critical objectives to advance towards the initiation of the U.S. pivotal trial," said Alex Ovadia, chief executive officer of Check-Cap. "The expansion of our manufacturing capacity and the entire production process is expected to secure the robust supply chain of C-Scan devices during the trial. The hire of Dr. Brenner has further strengthened our clinical team to support initiation and management of the planned U.S pivotal trial."
Mr. Ovadia added, "In addition, our team has continued to build and fortify our patent portfolio ahead of global product commercialization. The recent granting of the patent covering our proprietary tracking technology along with our total patent portfolio secure our exclusive rights to our technology worldwide and enhances shareholder value."
Financial Results for the Third Quarter Ended September 30, 2021
Research and development expenses were $3.0 million for the three months ended September 30, 2021, compared to $2.7 million for the same period in 2020. The increase is primarily due to a $0.3 million increase in salary and related expense and a $0.1 million increase in material and subcontractors' expenses, offset in part by a $0.1 million grant received from the Israel Innovation Authority, which reduced research and development expenses.
General and administrative expenses were $1.2 million for the three months ended September 30, 2021, compared to $1.0 million for the same period in 2020. The increase is primarily due to a $0.15 million increase in other general expenses and a $0.05 million increase in salary and related expense.
Operating loss was $4.3 million for the three months ended September 30, 2021, compared to $3.6 million for the same period in 2020.
Finance income was $22,000 for the three months ended September 30, 2021, compared to $13,000 for the same period in 2020.
Net loss was $4.2 million for the three months ended September 30, 2021, compared to $3.6 million for the same period in 2020.
Cash and cash equivalents, restricted cash and short-term bank deposits as of September 30, 2021 were $56.8 million, compared with $29.3 million as of June 30, 2021 and $18.1 million as of December 31, 2020. During the first quarter of 2021, certain warrant holders exercised warrants to purchase an aggregate 24,204,682 ordinary shares, which had been issued in 2020, at exercise prices ranging from $0.75-$0.80, which generated total gross proceeds of approximately $19.2 million to the Company. In July 2021, the Company completed the sale of 25,925,926 of the Company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Company's ordinary shares in a registered direct offering, which resulted in gross proceeds to the Company of $35.0 million or approximately $31.8 million net of offering expenses. The Company believes that it has sufficient capital to fund its ongoing operations and plans until well into 2023.
The number of outstanding ordinary shares as of September 30, 2021 was 96,404,949. As of November 2, 2021, the number of the Company's outstanding ordinary shares was 96,404,949.
Financial Results for the Nine Months Ended September 30, 2021
Research and development expenses were $8.2 million for the nine months ended September 30, 2021, compared to $7.2 million for the same period in 2020. The increase is primarily due to a $0.8 million increase in salary and related expense and a $0.7 million increase in material and subcontractors' expenses, offset in part by a $0.3 million grant received from the Israel Innovation Authority, which reduced research and development expenses, and a $0.2 million decrease in other expenses.
General and administrative expenses were $3.5 million for the nine months ended September 30, 2021, compared to $2.8 million for the same period in 2020. The increase is primarily due to a $0.2 million increase in salary and related expense, a $0.5 million increase in other general expenses mainly associated with directors and officers insurance liability and a $0.1 million increase in professional services expenses, offset in part by $0.1 million decrease in share-based compensation.
Operating loss was $11.7 million for the nine months ended September 30, 2021, compared to $10.0 million for the same period in 2020.
Finance income was $18,000 for the nine months ended September 30, 2021, compared to $62,000 for the same period in 2020.
Net loss was $11.7 million for the nine months ended September 30, 2021, compared to $9.9 million for the same period in 2020.
Net cash used in operating activities was $11.9 million for the nine months ended September 30, 2021, compared to $9.6 million for the same period in 2020.
About Check-Cap
Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2020 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
This email address is being protected from spambots. You need JavaScript enabled to view it.
Meirav Gomeh-Bauer
LifeSci Advisors, LLC
+972(0)-54-476-4979
This email address is being protected from spambots. You need JavaScript enabled to view it.
CHECK CAP LTD | |||||
September 30, | December 31, | ||||
2 0 2 1 | 2 0 2 0 | ||||
Assets | |||||
Current assets | |||||
Cash and cash equivalents | 39,607 | 7,703 | |||
Restricted cash | 350 | 350 | |||
Short-term bank deposit | 16,812 | 10,079 | |||
Prepaid expenses and other current assets | 1,117 | 285 | |||
Total current assets | 57,886 | 18,417 | |||
Non-current assets | |||||
Property and equipment, net | 1,565 | 823 | |||
Operating lease | 1,124 | 398 | |||
Total non-current assets | 2,689 | 1,221 | |||
Total assets | 60,575 | 19,638 | |||
Liabilities and shareholders' equity | |||||
Current liabilities | |||||
Accounts payable and accruals | |||||
Trade | 1,288 | 862 | |||
Other | 501 | 345 | |||
Employees and payroll accruals | 1,547 | 1,510 | |||
Operating lease liabilities | 328 | 264 | |||
Total current liabilities | 3,664 | 2,981 | |||
Non-current liabilities | |||||
Royalties provision | 178 | 154 | |||
Operating lease liabilities | 792 | 125 | |||
Total non-current liabilities | 970 | 279 | |||
Shareholders' equity | |||||
Share capital, Ordinary shares, 2.4 NIS par value (360,000,000 authorized shares as of September 30, 2021 and | |||||
31, 2020; 96,404,949 and 46,239,183 shares issued and outstanding as of September 30, 2021 and December 31, | |||||
respectively) | 68,782 | 31,646 | |||
Additional paid-in capital | 89,867 | 75,715 | |||
Accumulated deficit | (102,708) | (90,983) | |||
Total shareholders' equity | 55,941 | 16,378 | |||
Total liabilities and shareholders' equity | 60,575 | 19,638 | |||
CHECK CAP LTD | ||||||||
CONSOLIDATED UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS | ||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||
Nine months ended September | Three months ended September | |||||||
30, | 30, | |||||||
2021 | 2020 | 2021 | 2020 | |||||
Research and development expenses, net | 8,223 | 7,177 | 3,036 | 2,664 | ||||
General and administrative expenses | 3,520 | 2,822 | 1,227 | 967 | ||||
Operating loss | 11,743 | 9,999 | 4,263 | 3,631 | ||||
Finance Income, net | 18 | 62 | 22 | 13 | ||||
Loss before income tax | 11,725 | 9,937 | 4,241 | 3,618 | ||||
Net loss for the period | 11,725 | 9,937 | 4,241 | 3,618 | ||||
Loss per share: | ||||||||
Net loss per ordinary share basic and diluted | 0.15 | 0.40 | 0.04 | 0.09 | ||||
Weighted average number of ordinary shares outstanding - basic | 78,238,314 | 25,017,699 | 95,853,149 | 41,518,827 | ||||
CHECK CAP LTD. | ||||||||||||||||
CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | ||||||||||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||||||||||
Number of | Additional |
Total | ||||||||||||||
Ordinary | paid-in | Accumulated | shareholders' | |||||||||||||
Shares | Amount | capital | deficit | equity | ||||||||||||
Balance as of January 1, 2021 | 46,239,183 | $ | 31,646 | $ | 75,715 | $ | (90,983) | $ | 16,378 | |||||||
Exercise of warrants, net of issuance | ||||||||||||||||
an amount of $22 | 24,204,682 | $ | 18,099 | $ | 1,120 | - | $ | 19,219 | ||||||||
Issuance of ordinary shares and | - | |||||||||||||||
in the July Financing, net | ||||||||||||||||
of issuance expenses in an | ||||||||||||||||
$3,199 | 25,925,926 | $ | 19,011 | $ | 12,790 | $ | 31,801 | |||||||||
RSU's vesting | 35,158 | $ | 26 | (26) | - | |||||||||||
Share-based compensation | - | - | $ | 268 | $ | 268 | ||||||||||
Net loss | - | - | - | $ | (11,725) | $ | (11,725) | |||||||||
Balance as of September 30, 2021 | 96,404,949 | $ | 68,782 | $ | 89,867 | $ | (102,708) | $ | 55,941 | |||||||
Balance as of January 1, 2020 | 8,272,908 | $ | 5,407 | $ | 77,964 | $ | (77,137) | $ | 6,234 | |||||||
Issuance of ordinary shares in | ||||||||||||||||
placement, net of issuance | ||||||||||||||||
an amount of approximately $30 | 2,720,178 | $ | 1,894 | $ | 2,837 | - | $ | 4,731 | ||||||||
Issuance of ordinary shares and | ||||||||||||||||
in the April – May 2020 Financings, | ||||||||||||||||
of issuance expenses in an amount of $ | ||||||||||||||||
1,361 | 19,166,670 | $ | 13,039 | $ | (2,900) | $ | 10,139 | |||||||||
Issuance of ordinary shares and | ||||||||||||||||
in | ||||||||||||||||
a warrant exercise financing, net of | ||||||||||||||||
Issuance expenses in an amount of | 16,054,223 | $ | 11,290 | $ | (2,578) | - | $ | 8,712 | ||||||||
RSU's vesting | 19,317 | $ | 12 | $ | (12) | - | - | |||||||||
Share-based compensation | - | - | $ | 317 | - | $ | 317 | |||||||||
Net loss | - | - | - | $ | (9,937) | (9,937) | ||||||||||
Balance as of September 30, 2020 | 46,233,296 | $ | 31,642 | $ | 75,628 | $ | (87,074) | $ | 20,196 | |||||||
CHECK CAP LTD. | ||||||||||||||
CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | ||||||||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||||||||
Number of | Additional | Total | ||||||||||||
Ordinary | paid-in | Accumulated | shareholders' | |||||||||||
Shares | Amount | capital | deficit | equity | ||||||||||
Balance as of June 30, 2021 | 70,473,641 | $ | 49,767 | $ | 76,951 | $ | (98,467) | $ | 28,251 | |||||
Issuance of ordinary shares and | - | |||||||||||||
in the July Financing, net | ||||||||||||||
of issuance expenses in an | ||||||||||||||
$3,199 | 25,925,926 | $ | 19,011 | $ | 12,790 | $ | 31,801 | |||||||
RSU's vesting | 5,382 | $ | 4 | (4) | - | |||||||||
Share-based compensation | - | - | $ | 130 | $ | 130 | ||||||||
Net loss | - | - | - | $ | (4,241) | $ | (4,241) | |||||||
Balance as of September 30, 2021 | 96,404,949 | $ | 68,782 | $ | 89,867 | $ | (102,708) | $ | 55,941 | |||||
Balance as of June 30, 2020 | 30,172,943 | $ | 20,348 | $ | 78,110 | $ | (83,546) | $ | 15,002 | |||||
Issuance of ordinary shares and | ||||||||||||||
in | ||||||||||||||
a warrant exercise financing, net of | ||||||||||||||
Issuance expenses in an amount of | 16,054,223 | $ | 11,290 | $ | (2,578) | - | $ | 8,712 | ||||||
RSU's vesting | 6,130 | $ | 4 | $ | (4) | - | - | |||||||
Share-based compensation | - | - | $ | 100 | - | $ | 100 | |||||||
Net loss | - | - | - | $ | (3,618) | (3,618) | ||||||||
Balance as of September 30, 2020 | 46,233,296 | $ | 31,642 | $ | 75,628 | $ | (87,074) | $ | 20,196 | |||||
CHECK-CAP LTD. | |||
CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands, except share and per share data)
| |||
Nine months ended | |||
September | |||
2021 | 2020 | ||
CASH FLOWS FROM OPERATING ACTIVITIES | |||
Net loss | (11,725) | (9,937) | |
Adjustments required to reconcile net loss to net cash used in operating activities: | |||
Depreciation | 139 | 107 | |
Share-based compensation | 268 | 317 | |
Financial income, net | (47) | (27) | |
Changes in assets and liabilities items: | |||
Decrease (increase) in prepaid and other current assets and non-current assets | (819) | 106 | |
Increase (decrease) in trade accounts payable, accruals and other current liabilities | 243 | (295) | |
Increase in employees and payroll accruals | 37 | 106 | |
Increase in royalties provision | 24 | 6 | |
Net cash used in operating activities | (11,880) | (9,617) | |
CASH FLOWS FROM INVESTING ACTIVITIES | |||
Purchase of property and equipment | (743) | (293) | |
Investment in short-term bank and other deposits | (6,700) | (15,003) | |
Net cash provided by (used in) investing activities | (7,443) | (15,296) | |
CASH FLOWS FROM FINANCING ACTIVITIES | |||
Exercise of warrants into ordinary shares, net of issuance expenses | 19,219 | - | |
Issuance of ordinary shares in the registered direct offerings, net of issuance expenses | 32,008 | - | |
Issuance of ordinary shares in private placement, net of issuance expenses | - | 4,731 | |
Issuance of ordinary shares in the registered direct offerings, net of issuance expenses | 10,139 | ||
Issuance of ordinary shares and warrants in a warrant exercise financing, net of | - | 8,712 | |
Net cash provided by financing activities | 51,227 | 23,582 | |
Net increase (decrease) in cash, cash equivalents and restricted cash | 31,904 | (1,331) | |
Cash, cash equivalents and restricted cash at the beginning of the period | 8,053 | 8,035 | |
Cash, cash equivalents and restricted cash at the end of the period | 39,957 | 6,704 | |
Supplemental disclosure of non-cash flow information: | |||
Purchase of property and equipment included in accounts payable and accrued | 133 | 22 | |
Assets acquired under operating leases | 968 | 140 | |
Financing fees included in account payable | 207 | ||
| Last Trade: | US$0.59 |
| Daily Change: | 0.02 3.44 |
| Daily Volume: | 33,496 |
| Market Cap: | US$3.450M |
November 28, 2023 November 27, 2023 November 13, 2023 November 06, 2023 August 16, 2023 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
